Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors

Hematology/Oncology Clinics of North America

Volumn 31, Issue 4, 2017, Pages 589-612

  Patel, Ami B ^a   O'Hare, Thomas ^a   Deininger, Michael W ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

BCR ABL1; Chronic myeloid leukemia (CML); Drug resistance; Mutation; Treatment free remission (TFR); Tyrosine kinase inhibitor (TKI)

Indexed keywords

ABELSON KINASE; ASCIMINIB; AXITINIB; BAFETINIB; BCR ABL PROTEIN; BCR ABL1 PROTEIN; BOSUTINIB; DACTOLISIB; DANUSERTIB; DASATINIB; HISTAMINE H2 RECEPTOR ANTAGONIST; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; NILOTINIB; ORGANIC CATION TRANSPORTER 1; PEGINTERFERON; PHOSPHATIDYLINOSITOL 3 KINASE; PIOGLITAZONE; PONATINIB; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; PROTON PUMP INHIBITOR; RADOTINIB; RAF PROTEIN; REBASTINIB; RUXOLITINIB; SELINEXOR; STAT3 PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; PROTEIN KINASE INHIBITOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTERY OCCLUSION; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CHRONIC MYELOID LEUKEMIA; CYTOPENIA; DRUG BIOAVAILABILITY; DRUG DOSE INTENSIFICATION; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKEMIA STEM CELL; MINIMAL RESIDUAL DISEASE; MINIMUM PLASMA CONCENTRATION; MONOTHERAPY; NONHUMAN; NUCLEOCYTOPLASMIC TRANSPORT; OVERALL SURVIVAL; PHILADELPHIA CHROMOSOME POSITIVE CELL; POINT MUTATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; TUMOR REGRESSION; ANTAGONISTS AND INHIBITORS; BIOAVAILABILITY; CELL SURVIVAL; CHEMISTRY; DOSE RESPONSE; DRUG DEVELOPMENT; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOTHERAPY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MOLECULAR MODEL; MOLECULARLY TARGETED THERAPY; MUTATION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL AVAILABILITY; BIOMARKERS; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; IMMUNOTHERAPY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MODELS, MOLECULAR; MOLECULAR TARGETED THERAPY; MUTATION; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 85021771044     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2017.04.007     Document Type: Review

References (129)

1. SEER cancer statistics factsheets: chronic myeloid leukemia. Bethesda (MD): National Cancer Institute. Available at: http://seer.cancer.gov/statfacts/html/cmyl.html. Accessed November 17, 2016.
2. Ren, R., Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 5 (2005), 172–183.
3. Bower, H., Bjorkholm, M., Dickman, P.W., et al. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol 34 (2016), 2851–2857.
4. Steegmann, J.L., Baccarani, M., Breccia, M., et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia 30:8 (2016), 1648–1671.
5. Baccarani, M., Deininger, M.W., Rosti, G., et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122 (2013), 872–884.
6. O'Brien, S., Radich, J.P., Abboud, C.N., et al. Chronic myelogenous leukemia, version 1.2015. J Natl Compr Canc Netw 12 (2014), 1590–1610.
7. Press, R.D., Galderisi, C., Yang, R., et al. A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response. Clin Cancer Res 13 (2007), 6136–6143.
8. Hochhaus, A., Chronic myelogenous leukemia (CML): resistance to tyrosine kinase inhibitors. Ann Oncol 17:Suppl 10 (2006), x274–x279.
9. Treiber, D.K., Shah, N.P., Ins and outs of kinase DFG motifs. Chem Biol 20 (2013), 745–746.
10. Zhang, J., Yang, P.L., Gray, N.S., Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 9 (2009), 28–39.
11. Schindler, T., Bornmann, W., Pellicena, P., et al. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289 (2000), 1938–1942.
12. Vajpai, N., Strauss, A., Fendrich, G., et al. Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib. J Biol Chem 283 (2008), 18292–18302.
13. Weisberg, E., Manley, P.W., Breitenstein, W., et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7 (2005), 129–141.
14. Levinson, N.M., Boxer, S.G., Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain. PLoS One, 7, 2012, e29828.
15. Zhou, T., Commodore, L., Huang, W.S., et al. Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance. Chem Biol Drug Des 77 (2011), 1–11.
16. Davis, M.I., Hunt, J.P., Herrgard, S., et al. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol 29 (2011), 1046–1051.
17. Shah, N.P., Nicoll, J.M., Nagar, B., et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2 (2002), 117–125.
18. Branford, S., Rudzki, Z., Walsh, S., et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 102 (2003), 276–283.
19. Hochhaus, A., Kreil, S., Corbin, A.S., et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16 (2002), 2190–2196.
20. von Bubnoff, N., Peschel, C., Duyster, J., Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back. Leukemia 17 (2003), 829–838.
21. Zabriskie, M.S., Eide, C.A., Tantravahi, S.K., et al. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell 26 (2014), 428–442.
22. Soverini, S., Colarossi, S., Gnani, A., et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 12 (2006), 7374–7379.
23. Roche-Lestienne, C., Soenen-Cornu, V., Grardel-Duflos, N., et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 100 (2002), 1014–1018.
24. Willis, S.G., Lange, T., Demehri, S., et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 106 (2005), 2128–2137.
25. O'Hare, T., Eide, C.A., Deininger, M.W., Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 110 (2007), 2242–2249.
26. O'Hare, T., Zabriskie, M.S., Eiring, A.M., et al. Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat Rev Cancer 12 (2012), 513–526.
27. Apperley, J.F., Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 8 (2007), 1018–1029.
28. Gorre, M.E., Mohammed, M., Ellwood, K., et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293 (2001), 876–880.
29. Eide, C.A., O'Hare, T., Chronic myeloid leukemia: advances in understanding disease biology and mechanisms of resistance to tyrosine kinase inhibitors. Curr Hematol Malig Rep 10 (2015), 158–166.
30. Weisberg, E., Manley, P., Mestan, J., et al. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer 94 (2006), 1765–1769.
31. Jabbour, E., Hochhaus, A., Cortes, J., et al. Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history. Leukemia 24 (2010), 6–12.
32. Redaelli, S., Piazza, R., Rostagno, R., et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol 27 (2009), 469–471.
33. O'Hare, T., Shakespeare, W.C., Zhu, X., et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16 (2009), 401–412.
34. Deininger, M.W., Hodgson, J.G., Shah, N.P., et al. Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. Blood 127 (2016), 703–712.
35. Barnes, D.J., Palaiologou, D., Panousopoulou, E., et al. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Res 65 (2005), 8912–8919.
36. Modi, H., McDonald, T., Chu, S., et al. Role of BCR/ABL gene-expression levels in determining the phenotype and imatinib sensitivity of transformed human hematopoietic cells. Blood 109 (2007), 5411–5421.
37. Milojkovic, D., Apperley, J., Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia. Clin Cancer Res 15 (2009), 7519–7527.
38. White, D.L., Dang, P., Engler, J., et al. Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J Clin Oncol 28 (2010), 2761–2767.
39. White, D.L., Saunders, V.A., Dang, P., et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 110 (2007), 4064–4072.
40. White, D.L., Radich, J., Soverini, S., et al. Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib. Haematologica 97 (2012), 907–914.
41. White, D.L., Saunders, V.A., Dang, P., et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 108 (2006), 697–704.
42. Hiwase, D.K., Saunders, V., Hewett, D., et al. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clin Cancer Res 14 (2008), 3881–3888.
43. Lu, L., Saunders, V.A., Leclercq, T.M., et al. Ponatinib is not transported by ABCB1, ABCG2 or OCT-1 in CML cells. Leukemia 29 (2015), 1792–1794.
44. Eadie, L.N., Hughes, T.P., White, D.L., Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib. Clin Pharmacol Ther 95 (2014), 294–306.
45. Sen, R., Natarajan, K., Bhullar, J., et al. The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2. Mol Cancer Ther 11 (2012), 2033–2044.
46. Eadie, L.N., Dang, P., Saunders, V.A., et al. The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment. Leukemia 31:1 (2017), 75–82.
47. Giannoudis, A., Davies, A., Harris, R.J., et al. The clinical significance of ABCC3 as an imatinib transporter in chronic myeloid leukaemia. Leukemia 28 (2014), 1360–1363.
48. Agrawal, M., Hanfstein, B., Erben, P., et al. MDR1 expression predicts outcome of Ph+ chronic phase CML patients on second-line nilotinib therapy after imatinib failure. Leukemia 28 (2014), 1478–1485.
49. Ni, L.N., Li, J.Y., Miao, K.R., et al. Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia. Med Oncol 28 (2011), 265–269.
50. Dulucq, S., Bouchet, S., Turcq, B., et al. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 112 (2008), 2024–2027.
51. Haouala, A., Widmer, N., Duchosal, M.A., et al. Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood 117 (2011), e75–e87.
52. Takahashi, N., Miura, M., Niioka, T., et al. Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients. Cancer Chemother Pharmacol 69 (2012), 999–1004.
53. Eley, T., Luo, F.R., Agrawal, S., et al. Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects. J Clin Pharmacol 49 (2009), 700–709.
54. Wagle, M., Eiring, A.M., Wongchenko, M., et al. A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Leukemia 30 (2016), 1493–1501.
55. Eiring, A.M., Khorashad, J.S., Anderson, D.J., et al. Beta-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia. Leukemia 29 (2015), 2328–2337.
56. Eiring, A.M., Kraft, I.L., Page, B.D., et al. STAT3 as a mediator of BCR-ABL1-independent resistance in chronic myeloid leukemia. Leuk Suppl 3 (2014), S5–S6.
57. Traer, E., MacKenzie, R., Snead, J., et al. Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors. Leukemia 26 (2012), 1140–1143.
58. Bewry, N.N., Nair, R.R., Emmons, M.F., et al. Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance. Mol Cancer Ther 7 (2008), 3169–3175.
59. Skorski, T., Kanakaraj, P., Nieborowska-Skorska, M., et al. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 86 (1995), 726–736.
60. Burchert, A., Wang, Y., Cai, D., et al. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia 19 (2005), 1774–1782.
61. Okabe, S., Tauchi, T., Tanaka, Y., et al. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation. Cancer Biol Ther 15 (2014), 207–215.
62. Chu, S., Holtz, M., Gupta, M., et al. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells. Blood 103 (2004), 3167–3174.
63. Ma, L., Shan, Y., Bai, R., et al. A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia. Sci Transl Med, 6, 2014, 252ra121.
64. Packer, L.M., Rana, S., Hayward, R., et al. Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia. Cancer Cell 20 (2011), 715–727.
65. Asmussen, J., Lasater, E.A., Tajon, C., et al. MEK-dependent negative feedback underlies BCR-ABL-mediated oncogene addiction. Cancer Discov 4 (2014), 200–215.
66. Khorashad, J.S., Eiring, A.M., Mason, C.C., et al. shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance. Blood 125 (2015), 1772–1781.
67. Walker, C.J., Oaks, J.J., Santhanam, R., et al. Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias. Blood 122 (2013), 3034–3044.
68. Scott, M.T., Korfi, K., Saffrey, P., et al. Epigenetic reprogramming sensitizes CML stem cells to combined EZH2 and tyrosine kinase inhibition. Cancer Discov 6:11 (2016), 1248–1257.
69. Xie, H., Peng, C., Huang, J., et al. Chronic myelogenous leukemia initiating cells require Polycomb group protein EZH2. Cancer Discov 6:11 (2016), 1237–1247.
70. Zhang, B., Li, M., McDonald, T., et al. Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-beta-catenin signaling. Blood 121 (2013), 1824–1838.
71. Ge, X., Wang, X., Role of Wnt canonical pathway in hematological malignancies. J Hematol Oncol, 3, 2010, 33.
72. Zhao, C., Blum, J., Chen, A., et al. Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell 12 (2007), 528–541.
73. Lim, S., Saw, T.Y., Zhang, M., et al. Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function. Proc Natl Acad Sci U S A 110 (2013), E2298–E2307.
74. Wu, J., Meng, F., Lu, H., et al. Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells. Blood 111 (2008), 3821–3829.
75. Wu, J., Meng, F., Kong, L.Y., et al. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase. J Natl Cancer Inst 100 (2008), 926–939.
76. Donato, N.J., Wu, J.Y., Stapley, J., et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101 (2003), 690–698.
77. O'Hare, T., Eide, C.A., Deininger, M.W., Persistent LYN signaling in imatinib-resistant, BCR-ABL-independent chronic myelogenous leukemia. J Natl Cancer Inst 100 (2008), 908–909.
78. Ng, K.P., Manjeri, A., Lee, K.L., et al. Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition. Blood 123 (2014), 3316–3326.
79. Irvine, D.A., Zhang, B., Kinstrie, R., et al. Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia. Sci Rep, 6, 2016, 25476.
80. Wu, L., Yu, J., Chen, R., et al. Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells. Clin Cancer Res 21 (2015), 833–843.
81. Kobayashi, C.I., Takubo, K., Kobayashi, H., et al. The IL-2/CD25 axis maintains distinct subsets of chronic myeloid leukemia-initiating cells. Blood 123 (2014), 2540–2549.
82. Chen, Y., Peng, C., Abraham, S.A., et al. Arachidonate 15-lipoxygenase is required for chronic myeloid leukemia stem cell survival. J Clin Invest 124 (2014), 3847–3862.
83. Zhang, B., Li, L., Chen, C.C., et al. Knockdown (KD) of Mir-126 expression enhances tyrosine kinase inhibitor (TKI)-mediated targeting of chronic myelogenous leukemia (CML) stem cells. Blood, 126, 2015, 51.
84. Dierks, C., Beigi, R., Guo, G.R., et al. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell 14 (2008), 238–249.
85. Chen, Y., Hu, Y., Zhang, H., et al. Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nat Genet 41 (2009), 783–792.
86. Neviani, P., Harb, J.G., Oaks, J.J., et al. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest 123 (2013), 4144–4157.
87. Cramer-Morales, K., Nieborowska-Skorska, M., Scheibner, K., et al. Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile. Blood 122 (2013), 1293–1304.
88. Peng, C., Brain, J., Hu, Y., et al. Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells. Blood 110 (2007), 678–685.
89. Li, L., Wang, L., Li, L., et al. Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell 21 (2012), 266–281.
90. Bellodi, C., Lidonnici, M.R., Hamilton, A., et al. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest 119 (2009), 1109–1123.
91. Ito, K., Bernardi, R., Morotti, A., et al. PML targeting eradicates quiescent leukaemia-initiating cells. Nature 453 (2008), 1072–1078.
92. Huang, W., Luan, C.H., Hjort, E.E., et al. The role of Fas-associated phosphatase 1 in leukemia stem cell persistence during tyrosine kinase inhibitor treatment of chronic myeloid leukemia. Leukemia 30 (2016), 1502–1509.
93. Jiang, Q., Crews, L.A., Barrett, C.L., et al. ADAR1 promotes malignant progenitor reprogramming in chronic myeloid leukemia. Proc Natl Acad Sci U S A 110 (2013), 1041–1046.
94. Reavie, L., Buckley, S.M., Loizou, E., et al. Regulation of c-Myc ubiquitination controls chronic myelogenous leukemia initiation and progression. Cancer Cell 23 (2013), 362–375.
95. Abraham, S.A., Hopcroft, L.E., Carrick, E., et al. Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells. Nature 534 (2016), 341–346.
96. Hurtz, C., Hatzi, K., Cerchietti, L., et al. BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. J Exp Med 208 (2011), 2163–2174.
97. Neviani, P., Santhanam, R., Oaks, J.J., et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest 117 (2007), 2408–2421.
98. Goff, D.J., Court Recart, A., Sadarangani, A., et al. A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition. Cell Stem Cell 12 (2013), 316–328.
99. Wylie, A., Schoepfer, J., Berellini, G., et al. ABL001, a potent allosteric inhibitor of BCR-ABL, prevents emergence of resistant disease when administered in combination with nilotinib in an in vivo murine model of chronic myeloid leukemia. Blood, 124, 2014, 398.
100. Ottmann, O.G., Alimena, G., DeAngelo, D.J., et al. ABL001, a potent, allosteric inhibitor of BCR-ABL, exhibits safety and promising single- agent activity in a phase I study of patients with CML with failure of prior TKI therapy. Blood, 126, 2015, 138.
101. Smith, B.D., Hood, M.M., Kaufman, M.D., et al. Abstract B78: rebastinib, a small molecule TIE2 kinase inhibitor, prevents primary tumor growth and lung metastasis in the PyMT breast cancer model. Cancer Res, 73, 2013, B78.
102. Santos, F.P., Kantarjian, H., Cortes, J., et al. Bafetinib, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia. Curr Opin Investig Drugs 11 (2010), 1450–1465.
103. Borthakur, G., Dombret, H., Schafhausen, P., et al. A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy. Haematologica 100 (2015), 898–904.
104. Zabriskie, M.S., Eide, C.A., Yan, D., et al. Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia. Leukemia 30 (2016), 1418–1421.
105. Pemovska, T., Johnson, E., Kontro, M., et al. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation. Nature 519 (2015), 102–105.
106. Kwak, J.-Y., Kim, H., Kim, J.A., et al. Efficacy and safety of radotinib compared with imatinib in newly diagnosed chronic phase chronic myeloid leukemia patients: 12 months result of phase 3 clinical trial. Blood, 126, 2015, 476.
107. Zabriskie, M.S., Vellore, N.A., Gantz, K.C., et al. Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1. Leukemia 29 (2015), 1939–1942.
108. Bhalla, S., Tremblay, D., Mascarenhas, J., Discontinuing tyrosine kinase inhibitor therapy in chronic myelogenous leukemia: current understanding and future directions. Clin Lymphoma Myeloma Leuk 16 (2016), 488–494.
109. Saussele, S., Richter, J., Hochhaus, A., et al. The concept of treatment-free remission in chronic myeloid leukemia. Leukemia 30:8 (2016), 1638–1647.
110. Talpaz, M., Hehlmann, R., Quintas-Cardama, A., et al. Re-emergence of interferon-alpha in the treatment of chronic myeloid leukemia. Leukemia 27 (2013), 803–812.
111. Preudhomme, C., Guilhot, J., Nicolini, F.E., et al. Imatinib plus peginterferon Alfa-2a in chronic myeloid leukemia. N Engl J Med 363 (2010), 2511–2521.
112. Simonsson, B., Gedde-Dahl, T., Markevärn, B., et al. Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. Blood 118 (2011), 3228–3235.
113. Hochhaus, A., Saglio, G., Hughes, T.P., et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 30 (2016), 1044–1054.
114. Hjorth-Hansen, H., Stentoft, J., Richter, J., et al. Safety and efficacy of the combination of pegylated interferon-alpha2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients. Leukemia 30 (2016), 1853–1860.
115. Nicolini, F.E., Etienne, G., Dubruille, V., et al. Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study. Lancet Haematol 2 (2015), e37–e46.
116. Roy, L., Chomel, J.C., Guilhot, J., et al. Combination of dasatinib and peg-interferon alpha 2b in chronic phase chronic myeloid leukemia (CP-CML) first line: preliminary results of a phase II trial, from the French Intergroup of CML (Fi-LMC). Blood, 126, 2015, 134.
117. Cortes, J., Saglio, G., Baccarani, M., et al. Final study results of the phase 3 dasatinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) trial (DASISION, CA180-056). Blood, 124, 2014, 152.
118. Pinilla-Ibarz, J., Cathcart, K., Korontsvit, T., et al. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood 95 (2000), 1781–1787.
119. Bocchia, M., Gentili, S., Abruzzese, E., et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet 365 (2005), 657–662.
120. Molldrem, J.J., Lee, P.P., Wang, C., et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 6 (2000), 1018–1023.
121. Rezvani, K., Yong, A.S., Mielke, S., et al. Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies. Haematologica 96 (2011), 432–440.
122. Gao, L., Bellantuono, I., Elsasser, A., et al. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 95 (2000), 2198–2203.
123. Dubrovsky, L., Pankov, D., Brea, E.J., et al. A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias. Blood 123 (2014), 3296–3304.
124. Järås, M., Johnels, P., Hansen, N., et al. Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein. Proc Natl Acad Sci U S A 107 (2010), 16280–16285.
125. Frolova, O., Benito, J., Brooks, C., et al. SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia. Br J Haematol 166 (2014), 862–874.
126. Lin, H., Chen, M., Rothe, K., et al. Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells. Oncotarget 5 (2014), 8637–8650.
127. Gallipoli, P., Cook, A., Rhodes, S., et al. JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo. Blood 124 (2014), 1492–1501.
128. Prost, S., Relouzat, F., Spentchian, M., et al. Erosion of the chronic myeloid leukaemia stem cell pool by PPARgamma agonists. Nature 525 (2015), 380–383.
129. Huang, X., Cortes, J., Kantarjian, H., Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer 118 (2012), 3123–3127.